# Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

> **NCT02491411** · NA · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 5 (actual)

## Conditions studied

- Hormone-Resistant Prostate Cancer
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Enzalutamide
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02491411
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study is terminated due to lower enrollment
- **Last updated:** 2018-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02491411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02491411, "Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02491411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*